Biomerieux, Inc.

Centre National De La Recherche Scientifique

Institut Curie

Biomerieux Sa

Université Claude Bernard Lyon I

Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

Hospices Civils De Lyon

Chu De Dijon

Jean-Philippe Charrier

Genevieve Choquet-Kastylevsky

Yannick Charretier

Corinne Beaulieu

Dominique Rolland

Gilles Zambardi

Yasemin Ataman-Onal

Sandrine Busseret

Tiphaine Cecchini

Christine Franceschi

Tanguy Fortin

Elodie Degout-Charmette

Arnaud Salvador

Bruno Colin

Laurent Drazek

Jean-Claude Raymond

Myriam-Laure Cubizolles

Dominique Decaux

Cécile Paris

Monique Arpin

Agnès Dupont-Filliard

Florence Rivera

Christine Peponnet

Marie-Hélène Charles

Geneviève Choquet-Kastylevsky

Chloé Bardet

Sylvie Pons

Laurent Veron

Christelle Compagnon

Florence Poirier

Véronique Lanet

Yasemin Ataman-Önal

Lucie Baujard-Lamotte

Yasemin Ataman-Oenal

Michel C Jolivet

Philippe Wandels

Odile Mejan-Letourneur

Denis Leroux

Jerome Lemoine

Nicole Battail-Poirot

Victoria Girard

Nadine Perrot

Régis Montvernay

Carole Tournel

Yasmin Ataman-Onal

Francois Vandenesch

Philippe Dugourd

Jéröme Lemoine

Jérôme Lemoine

Martin Welker

Olivier Dauwalder

Hader Haidous

Philippe Dufour

Sonia Chatellier

Jean Faivre

Odile Mejan-letourneur

François Vandenesch

A process for determining the sensitivity or resistance of at least one identified bacterium to at least one antibiotic, wherein the process includes the following steps: a) bringing a sample including bacterium into contact with the at least one antibiotic, the antibiotic inducing the rupture of the bacterial wall and/or of the cytoplasmic membrane and causing the release of the intracellular compounds of the bacterium when the bacterium is termed 'sensitive' to the at least one antibiotic, b) incubating the sample with the at least one antibiotic, c) purifying the sample by removing the intact bacteria and the cell debris, d) analyzing the purified sample by mass spectrometry, e) detecting the presence or absence of at least one peak of at least one protein characteristic of the bacterium, and f) determining the sensitivity or the resistance of the bacterial population to the antibiotic.

Mass spectrometry determination of the sensitivity or resistance of bacteria to an antibiotic

A method for quantifying at least one microorganism group via at least one mass spectrometry analysis is described. The method includes at least one separation and fragmentation step. The method moreover includes a step that involves measuring the amount of at least one representative peptide or at least one protein representing the microorganism group. The at least one representative peptide or the at least one protein is obtained after the at least one separation and fragmentation step and serves as a quantification marker(s). The amount of the quantification marker(s) is directly correlatable to the amount of the at least one microorganism group.

Method for quantifying at least one microorganism group via mass spectrometry

A method for determining the integrity of at least one complex based on at least one biological sample and at least one matrix, including at least the following steps:—acquiring at least one image,—analyzing the image sent by extracting light intensity values representative of at least one spectral band,—relating the light intensity values to one another to obtain representative spectral data,—determining a state of integrity of the complex by comparing each of the representative spectral data by similarity grouping with a determined similarity threshold,—triggering at least one first alert, by the analysis unit, when the representative data are similar to the first state of integrity or to the second state of integrity.

Method for determining the integrity of a deposit of a complex based on a biological sample and system for carrying out said method

A method for quantifying at least one microorganism group via at least one mass spectrometry analysis. The method includes at least one separation and fragmentation step. The method moreover includes a step that involves measuring the amount of at least one representative peptide or at least one protein representing the microorganism group. The at least one representative peptide or the at least one protein is obtained after the at least one separation and fragmentation step and serves as a quantification marker(s). The amount of the quantification marker(s) is directly correlatable to the amount of the at least one microorganism group.

The invention relates to a method for detecting a colorectal lesion likely to evolve into invasive colorectal cancer, in a patient, by determining the presence of Liver Fatty Acid-Binding Protein (LFABP), in a biological sample of the patient, distant form the lesion.

Method for detecting a colorectal lesion

A method assaying the levels of expression Apolipoprotein AI, Apolipoprotein AII, E-Cadherin, and Galectin-3 in a biological sample from a person having or suspected of having colorectal cancer. The sample is remote from any tumor.

Method of assaying Apolipoprotein AI for the in vitro diagnosis of colorectal cancer

The present invention relates to a method of obtaining peptides from procaryotic and/or eucaryotic cells.

Method for obtaining peptides

The aim of the present invention is a method of sampling all or part of a sample () of biological matter (), which is crude, enriched or cultured through contact with a culture medium (), such as agar, for example in a Petri dish, using a probe () equipped with a terminal end (), said sampling method comprising the steps of cooling the terminal end () of the probe (), sticking all or part of the sample () of biological matter () to be sampled through contact, or by applying a pressure exerted by the terminal end () onto the sample () of biological matter (), and sampling of all or part of the sample () of biological matter () so as to separate the sample () of biological matter () from the culture medium (), a method of depositing into a container () or onto an analysis plate () all or part of a sample () of biological matter () stuck onto a frosted terminal end () of a probe, said depositing method including a step of separating the terminal end () of the probe () from all or part of the sample () of biological matter (), as well as a device (), a kit and an apparatus () implementing these methods.

Method of sampling and/or depositing a sample of biological matter and device implementing such method

A method for characterizing at least one microorganism from a sample includes identifying the at least one microorganism and determining the properties of typing, potential resistance to at least one antimicrobial, and virulence factor. The properties of typing, resistance to at least one antimicrobial, and virulence factor for the at least one microorganism are determined by implementing mass spectrometry using proteins, peptides and/or metabolites as markers of the properties of typing, resistance to at least one antimicrobial, and virulence factor.

Method for characterizing at least one microorganism by means of mass spectrometry

A method of detection, for at least one microorganism contained in a sample, of at least one marker of resistance to a glycopeptide, including the detection, by mass spectrometry, of at least one peptide or protein of the microorganism. Preferably, the glycopeptide is vancomycin. Preferably, the peptide is derived from a protein of type vanA, vanB, vanC, vanD, vanE, vanG, vanL, vanM or vanN.

Method for detecting at least one mechanism of resistance to glycopeptides by mass spectrometry

A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7 and SEQ ID No.8. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Ezrin assay method for the in vitro diagnosis of colorectal cancer

The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Leukocyte Elastase Inhibitor tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Method of assaying leukocyte elastase inhibitor for the in vitro diagnosis of colorectal cancer

The present invention pertains to a method of detection, by mass spectrometry, of at least one marker of at least one mechanism of resistance to at least one antimicrobial, resistance of at least one microorganism contained in a sample, characterized in that the antimicrobial is a carbapenem, and said resistance markers are proteins or peptides. Preferably, said proteins or peptides are proteins from said microorganism.

Method of detecting at least one mechanism of resistance to carbapenems by mass spectrometry

The present invention pertains to a method of detection, by mass spectrometry, of at least one marker of at least one mechanism of resistance to at least one antimicrobial, resistance of at least one microorganism contained in a sample, characterised in that the antimicrobial is a cephalosporin, and said resistance markers are proteins or peptides. Preferably, said proteins or peptides are proteins from said microorganism.

Method of detecting at least one mechanism of resistance to cephalosporins by mass spectrometry

Growing community of inventors

Tassin la Demi Lune, France

Jean-Philippe Charrier